Legal & General Group Plc Reduces Position in Progyny, Inc. (NASDAQ:PGNY)

Legal & General Group Plc trimmed its holdings in Progyny, Inc. (NASDAQ:PGNY - Free Report) by 7.0% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 214,552 shares of the company's stock after selling 16,158 shares during the period. Legal & General Group Plc owned 0.25% of Progyny worth $3,701,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Barclays PLC lifted its stake in Progyny by 530.4% in the 3rd quarter. Barclays PLC now owns 706,157 shares of the company's stock worth $11,835,000 after purchasing an additional 594,140 shares in the last quarter. Tidal Investments LLC lifted its position in Progyny by 67.7% during the third quarter. Tidal Investments LLC now owns 60,722 shares of the company's stock worth $1,018,000 after buying an additional 24,507 shares in the last quarter. Franklin Resources Inc. boosted its stake in Progyny by 17.0% during the third quarter. Franklin Resources Inc. now owns 48,248 shares of the company's stock worth $759,000 after buying an additional 7,003 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Progyny by 341.4% in the 4th quarter. GAMMA Investing LLC now owns 1,611 shares of the company's stock worth $28,000 after acquiring an additional 1,246 shares during the last quarter. Finally, Central Pacific Bank Trust Division raised its holdings in shares of Progyny by 89.8% during the 4th quarter. Central Pacific Bank Trust Division now owns 13,250 shares of the company's stock worth $229,000 after acquiring an additional 6,270 shares during the period. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Progyny Price Performance

Shares of Progyny stock opened at $21.87 on Wednesday. The stock has a market capitalization of $1.87 billion, a price-to-earnings ratio of 37.71, a price-to-earnings-growth ratio of 2.39 and a beta of 1.33. The business has a 50-day moving average of $21.93 and a 200 day moving average of $18.94. Progyny, Inc. has a 12 month low of $13.39 and a 12 month high of $33.84.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on PGNY. Bank of America upped their price objective on shares of Progyny from $21.00 to $25.00 and gave the company a "buy" rating in a report on Tuesday, February 11th. Canaccord Genuity Group raised their price target on shares of Progyny from $17.00 to $23.00 and gave the stock a "hold" rating in a report on Friday, February 28th. JPMorgan Chase & Co. upped their price objective on Progyny from $17.00 to $23.00 and gave the company a "neutral" rating in a report on Tuesday, January 28th. Finally, BTIG Research raised Progyny from a "neutral" rating to a "buy" rating and set a $28.00 target price for the company in a research note on Monday, March 31st. Eight analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, Progyny presently has a consensus rating of "Hold" and a consensus price target of $23.64.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.